Unum Therapeutics Inc (UMRX) Receives $14.60 Consensus Target Price from Analysts

Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have received an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $14.60.

UMRX has been the subject of several analyst reports. SunTrust Banks dropped their target price on shares of Unum Therapeutics to $10.00 and set a “buy” rating for the company in a research report on Friday, March 29th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Unum Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Unum Therapeutics in a research report on Friday, March 29th. Finally, Cowen initiated coverage on shares of Unum Therapeutics in a research report on Tuesday, February 26th. They issued a “market perform” rating for the company.

Shares of NASDAQ:UMRX traded down $0.02 during midday trading on Friday, hitting $3.29. The stock had a trading volume of 44,755 shares, compared to its average volume of 100,871. The stock has a market capitalization of $99.09 million, a PE ratio of -2.37 and a beta of 2.25. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.11. Unum Therapeutics has a fifty-two week low of $3.03 and a fifty-two week high of $17.66.



Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, May 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.15 million. Unum Therapeutics had a negative net margin of 373.81% and a negative return on equity of 62.24%. On average, research analysts predict that Unum Therapeutics will post -1.35 EPS for the current fiscal year.

In related news, insider Seth Ettenberg sold 11,485 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $4.12, for a total transaction of $47,318.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. increased its position in Unum Therapeutics by 432.8% during the 4th quarter. American International Group Inc. now owns 12,531 shares of the company’s stock worth $55,000 after purchasing an additional 10,179 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in Unum Therapeutics during the 1st quarter worth approximately $61,000. Acadian Asset Management LLC acquired a new position in Unum Therapeutics during the 1st quarter worth approximately $61,000. Jane Street Group LLC acquired a new position in Unum Therapeutics during the 3rd quarter worth approximately $150,000. Finally, Rhumbline Advisers acquired a new position in Unum Therapeutics during the 1st quarter worth approximately $85,000. Institutional investors and hedge funds own 47.60% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: Net Income

Analyst Recommendations for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.